Business
Artelo is a clinical-stage biopharmaceutical company developing therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system.
Artelo remained pre-revenue, the net loss widened to $12.9M, and equity turned negative.
The read at a glance✓ Audited against SEC data
- Business mix — Lipid-signaling therapeuticsNote
- Revenue — No standard revenue fieldNote
- Profitability — Net loss widened 31.1%Watch
- Cash — Cash from ops was -$8.5MWatch
- Balance sheet — Equity turned negativeWatch
- Insiders — 0 buys / 0 sellsNote
- Accounting — Forensic screen unavailableNote
Leadership changes
From ARTELO BIOSCIENCES, INC.'s own filings, the day they're filed.
- Mark Spring · Chief Financial Officer · appointmenteff. 2025-11-01
- Gregory Gorgas · CFO · appointment
- Protection Period · departure
Latest filings
- 8-K · Company announcement2026-08-27
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-07-17
- DEF 14A · Annual proxy (pay & governance)2026-06-05
- 8-K · Company announcement2026-05-27
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ARTELO BIOSCIENCES, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.